2023-507518-28-00招募中3 期
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts‐2
Universitaetsklinikum Ulm AöR86 个研究点 分布在 8 个国家目标入组 423 人开始时间: 2023年12月21日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 423
- 试验地点
- 86
- 主要终点
- EFS in adult patients with newly diagnosed AML, defined as the time from randomization to treatment failure, death from any cause, relapse after achieving CR or CRi, or start of new (non-study) therapy due to confirmed molecular progression or relapse whichever occurs first. Treatment failure is defined as not attaining CR or CRi by induction chemotherapy, and EFS event time for treatment failure is date of randomization.
研究概览
简要总结
To assess if treatment with venetoclax, as compared to placebo, in combination with induction and consolidation therapy prolongs event-free survival (EFS) in adult patients with newly diagnosed AML, defining not achieving of CR or CRi as treatment failure.
研究设计
- 分配方式
- Randomized
- 主要目的
- Randomized Phase
- 盲法
- Double (Subject, Monitor, Investigator)
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Patients with newly diagnosed acute myeloid leukemia (AML) according to the International Consensus Classification (ICC)
- •Female patient must either: o Be of nonchildbearing potential: • Postmenopausal (defined as at least 1 year without any menses) • Documented surgically sterile (e.g. documented hysterectomy, bilateral oophorectomy, bilateral salpingectomy or congenital sterile) or status posthysterectomy (at least 1 month prior to screening) o Or, if of childbearing potential (not surgically sterile and not postmenopausal) • Not planning to become pregnant during the study and for 27 weeks after the final study drug administration • And have a negative urine or serum pregnancy test at screening • And, if heterosexually active, agree to consistently apply one highly effective* method of birth control in combination to a barrier method for the duration of the study and for 27 weeks after the final study drug administration. *Highly effective forms of birth control include Consistent and correct usage of established hormonal contraceptives that inhibit ovulation, for at least 1 month prior to taking study drug. (Hormonal contraception is only a highly effective method of birth control, if a combined (estrogen and progestogen containing) hormonal contraception or a progestogen-only hormonal contraception – both associated with inhibition of ovulation - is used.) Established intrauterine device (IUD) or intrauterine system (IUS), Bilateral tubal occlusion, Vasectomy - a vasectomy is a highly effective contraception method provided the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. Male is sterile due to a bilateral orchiectomy. Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual activity during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. *List is not all inclusive. Prior to enrolment, the investigator is responsible for confirming patient will utilize highly effective forms of birth control in combination with a barrier method according to locally accepted standards during the protocol defined period. • Female patient must agree not to breastfeed starting at screening and throughout the study period, and for 2 months and 1 week after the final study drug administration. • Female patient must not donate ova starting at screening and throughout the study period, and for 27 weeks after the final study drug administration.
- •Men must use a latex condom during any sexual contact with WOCBP, even if they have undergone a successful vasectomy and must agree to avoid to father a child (while on therapy and for 27 weeks after the final study drug administration). In addition, their female partners of childbearing potential have to use a highly effective method of birth control.
- •Male patient must not donate sperm starting at screening and throughout the study period and for 6 months after the final study drug administration.
- •Able to understand and willing to sign an informed consent form (ICF).
- •Age ≥ 18 years and ≤ 75 years
- •Patients considered eligible for intensive chemotherapy
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Molecular analysis centrally performed in AMLSG and HOVON laboratories.
- •Adequate renal function as evidenced by serum creatinine ≤ 2.0 × upper limit of normal (ULN) or creatinine clearance >40 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR).
- •Adequate hepatic function as evidenced by: o Serum total bilirubin ≤ 2.5 × ULN unless considered due to Gilbert’s disease, or leukemic involvement following approval by the Principal Investigators or Trial Coordinator of the study o Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 3.0 × ULN, unless considered due to leukemic involvement following approval by the Principal Investigators or Trial Coordinators of the study
- •No prior chemotherapy for AML except hydroxyurea for up to 14 days during the diagnostic screening phase for the control of peripheral leukemic blasts in patients with leukocytosis (e.g., white blood cell [WBC] counts > 25x109/L); patients may have had previous treatment with erythroid stimulating agents (ESA) or hypomethylating agents (HMAs) for an antecedent phase of MDS; ESA and HMAs have to be stopped at least four weeks before start of study treatment.
- •Patients must not have received a known strong or moderate CYP3A inducer 7 days before start of study treatment. Patients must have no known medical conditions requiring chronic therapy of moderate or strong CYP3A inducers.
排除标准
- •Acute promyelocytic leukemia (APL) with t(15;17)(q24.1;q21.1); PML-RARA; or one of the other pathognomonic variant chromosomal translocations/ fusion genes.
- •Conditions that limit the ingestion or gastrointestinal absorption of orally administered drugs.
- •Patients with a currently active second malignancy. Patients are not considered to have a currently active malignancy, if they have completed therapy and are considered by their physician to be at <30% risk of relapse within one year. However, patients with the following history/concurrent conditions are allowed: o Basal or squamous cell carcinoma of the skin; o Carcinoma in situ of the cervix; o Carcinoma in situ of the breast; o Incidental histologic finding of prostate cancer.
- •Receipt of live, attenuated vaccine within 30 days prior to the study inclusion (NOTE: patients, if enrolled, should not receive live vaccine during the study and until 6 months after the therapy).
- •Severe neurological or psychiatric disorder interfering with ability to give an informed consent.
- •Known or suspected hypersensitivity to any of the chemotherapeutic agents used.
- •No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician about study participation.
- •No consent for biobanking of patient’s biological specimens.
- •Participation in other prospective studies with anti-leukemic and/or investigational agents.
- •The patient is a pregnant or lactating woman, or plans to become pregnant during the study.
- •AML with t(9;22)(q34.1;q11.2);BCR::ABL1; or myeloid blast crisis of CML.
- •Patients with AML and activating FLT3 mutations who have access (including reimbursement) to treatment with a FLT3 inhibitor approved for first-line therapy of AML.
- •Prior treatment of MDS with intensive chemotherapy or allogeneic hematopoietic cell transplantation (HCT) with a curative intent
- •Significant active cardiac disease within 6 months prior to the start of study treatment, including: o New York Heart Association (NYHA) class III or IV congestive heart failure; o Myocardial infarction; o Unstable angina and/or stroke; o Severe cardiac arrhythmias o Left ventricular ejection fraction (LVEF) <40% by ultrasound obtained within 28 days prior to the start of study treatment.
- •Severe obstructive or restrictive ventilation disorder.
- •Clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid (CSF) during screening is only required, if there is a clinical suspicion of CNS involvement by leukemia during screening.
- •Active infection, including hepatitis B or hepatitis C antibody or Human Immunodeficiency Virus (HIV) infection, that is uncontrolled prior to first dose of study treatment and may interfere with the study objectives or which could expose the patient to undue risk through the participation in the clinical trial; an infection controlled with an approved antibiotic/ antiviral/ antifungal treatment that is not a strong or moderate CYP3A inducer is allowed.
- •Immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding and/or disseminated intravascular coagulation.
结局指标
主要结局
EFS in adult patients with newly diagnosed AML, defined as the time from randomization to treatment failure, death from any cause, relapse after achieving CR or CRi, or start of new (non-study) therapy due to confirmed molecular progression or relapse whichever occurs first. Treatment failure is defined as not attaining CR or CRi by induction chemotherapy, and EFS event time for treatment failure is date of randomization.
EFS in adult patients with newly diagnosed AML, defined as the time from randomization to treatment failure, death from any cause, relapse after achieving CR or CRi, or start of new (non-study) therapy due to confirmed molecular progression or relapse whichever occurs first. Treatment failure is defined as not attaining CR or CRi by induction chemotherapy, and EFS event time for treatment failure is date of randomization.
次要结局
- Overall survival (OS) in newly diagnosed AML patients, defined as the time from randomization to death due to any cause. Patients still alive or lost to follow up will be censored at the time they were last known to be alive.
- Rate of complete remission (CR) or CR with incomplete blood count recovery (CRi) rate in newly diagnosed AML patients defined as the proportion of AML patients with CR/CRi by the end of induction chemotherapy.
- Complete remission (CR) rates in newly diagnosed AML patients defined as the proportion of AML patients with CR by the end of induction chemotherapy.
- Rates of CR CR/CRh, and CR/CRi without measurable residual disease (CRMRD-, CR/CRhMRD-, CR/CRiMRD-) by the end of induction therapy, defined as the proportion of AML patients achieving CR, CR/CRh and CR/CRi with negativity for a genetic marker by RT-qPCR, and/or with negativity by multi-parameter flow cytometry, if studied pre-treatment.
- Relapse-free survival (RFS) in newly diagnosed AML patients, defined as the time from achievement of a remission (CR/CRh/CRi) following induction therapy, to morphologic relapse, start of new (non-study) therapy due to confirmed molecular progression or relapse or death from any cause. Patients who are not known to have relapsed, died or started new therapy due to confirmed molecular progression or relapse will be censored at the date of last clinical response assessment.
- Cumulative incidence of relapse (CIR) in newly diagnosed AML patients, measured from the date of achievement of a remission (CR/CRh/CRi) to date of relapse, or date of start of new (non-study) therapy due to confirmed molecular progression or relapse. Death in remission will be considered as a competing event. Patients who are not known to have relapsed, died or started new therapy due to molecular progression or relapse will be censored at the date of last clinical response assessment.
- Cumulative incidence of death (CID) in newly diagnosed AML patients, measured from the date of achievement of a remission (CR/CRh/CRi) to death without prior relapse (may it be morphologic relapse or confirmed molecular progression or relapse with subsequent start of new non-study therapy). Relapse after achieving CR/CRh/CRi or start of new therapy due to confirmed molecular progression or relapse will be considered as a competing event.
- Quality of life among AML patients as assessed by o EQ-5D-5L visual analogue scale (VAS) among AML patients o EORTC-QLQ-C30 global health status/QoL scale and QLQ-C30 subdomains and o PROMIS Cancer Fatigue short form, version 7a.
- Event-free survival in newly diagnosed AML patients, defined as the time from randomization to treatment failure, death from any cause, relapse after achieving CR, CRh or CRi, or start of new (non-study) therapy due to confirmed molecular progression or relapse whichever occurs first. Treatment failure is defined as not attaining CR, CRh or CRi by induction chemotherapy, i.e. if a patient’s best response during or at completion of the induction treatment is less than CR/CRh/CRi.
- Rate of complete remission (CR) or CR with partial hematologic recovery (CRh) in newly diagnosed AML patients defined as the proportion of AML patients with CR/CRh by the end of induction chemotherapy.
研究者
Hartmut Doehner
Scientific
Universitaetsklinikum Ulm AöR
研究点 (86)
Loading locations...
相似试验
已完成
2 期
A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic LeukemiaT-cell Prolymphocytic Leukemia (T-PLL)CancerLeukemiaNCT03873493AbbVie14
招募中
2 期
A phase 2 study of venetoclax in combination with low-dose cytarabine in relapsing acute myeloid leukemiaCancer - Leukaemia - Acute leukaemiaAcute Myeloid LeukemiaACTRN12619000746134Alfred Hospital32
招募中
1 期
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDSMyelodysplastic SyndromesAcute Myeloid LeukemiaNCT05342584Montefiore Medical Center99
撤回
2 期
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose TherapyMultiple MyelomaNCT03785184AbbVie
进行中（未招募）
不适用
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma [M15-654]jRCT2031200392AbbVie G.K.104